ABSTRACT
Resumo: Análises comparativas, baseadas em indicadores de desempenho clínico, para monitorar a qualidade da assistência hospitalar vêm sendo realizadas há décadas em vários países, com destaque para a razão de mortalidade hospitalar padronizada (RMHP). No Brasil, ainda são escassos os estudos e a adoção de instrumentos metodológicos que permitam análises regulares do desempenho das instituições. O objetivo deste artigo foi explorar o uso da RMHP para a comparação do desempenho dos hospitais remunerados pelo Sistema Único de Saúde (SUS). O Sistema de Informações Hospitalares foi a fonte de dados sobre as internações de adultos realizadas no Brasil entre 2017 e 2019. A abordagem metodológica para estimar a RMHP foi adaptada aos dados disponíveis e incluiu as causas de internação (diagnóstico principal) responsáveis por 80% dos óbitos. O número de óbitos esperados foi estimado por um modelo de regressão logística que incluiu variáveis preditoras amplamente descritas na literatura. A análise foi realizada em duas etapas: (i) nível da internação e (ii) nível do hospital. O modelo final de ajuste de risco apresentou estatística C de 0,774, valor considerado adequado. Foi observada grande variação da RMHP, especialmente entre os hospitais com pior desempenho (1,54 a 6,77). Houve melhor desempenho dos hospitais privados em relação aos hospitais públicos. Apesar de limites nos dados disponíveis e desafios ainda vislumbrados para a sua utilização mais refinada, a RMHP é aplicável e tem potencial para se tornar um elemento importante na avaliação do desempenho hospitalar no SUS.
Abstract: Comparative analyses based on clinical performance indicators to monitor the quality of hospital care have been carried out for decades in several countries, most notably the hospital standardized mortality ratio (HSMR). In Brazil, studies and the adoption of methodological tools that allow regular analysis of the performance of institutions are still scarce. This study aimed to assess the use of HSMR to compare the performance of hospitals funded by the Brazilian Unified National Health System (SUS). The Hospital Information System was the source of data on adult hospitalizations in Brazil from 2017 to 2019. The methodological approach to estimate HSMR was adapted to the available data and included the causes of hospitalization (main diagnosis) responsible for 80% of deaths. The number of expected deaths was estimated using a logistic regression model that included predictor variables widely described in the literature. The analysis was conducted in two stages: (i) hospitalization level and (ii) hospital level. The final risk adjustment model showed a C-statistic of 0.774, which is considered adequate. The variation in HSMR was wide, especially among the worst-performing hospitals (1.54 to 6.77). Private hospitals performed better than public hospitals. Although the limits of the available data and the challenges still face its more refined use, HSMR is applicable and has the potential to become an important tool for assessing hospital performance in the SUS.
Resumen: Durante décadas se han realizado en varios países análisis comparativos basados en indicadores de desempeño clínico para monitorear la calidad de la atención hospitalaria, con énfasis en la razón de mortalidad hospitalaria estandarizada (RMHE). En Brasil, aún son escasos los estudios y la adopción de instrumentos metodológicos que permitan análisis regulares del desempeño de las instituciones. El objetivo fue explorar el uso de la RMHE para comparar el desempeño de los hospitales remunerados por el Sistema Único de Salud (SUS). El Sistema de Información Hospitalaria fue la fuente de datos sobre las hospitalizaciones de adultos realizadas en Brasil entre el 2017 y el 2019. El enfoque metodológico para estimar la RMHE se adaptó a los datos disponibles e incluyó las causas de hospitalización (diagnóstico principal) responsables del 80% de las muertes. El número de muertes esperadas se estimó mediante un modelo de regresión logística que incluyó variables predictoras ampliamente descritas en la literatura. El análisis se realizó en dos etapas: (i) nivel de la hospitalización y (ii) nivel del hospital. El modelo final de ajuste de riesgo presentó una estadística C de 0,774, valor considerado adecuado. Se observó una gran variación en la RMHE, especialmente entre los hospitales con peor desempeño (1,54 a 6,77). Hubo un mejor desempeño de los hospitales privados en comparación con los hospitales públicos. A pesar de las limitaciones de los datos disponibles y de los desafíos aún previstos para su uso más refinado, la RMHE es aplicable y tiene el potencial de convertirse en un elemento importante en la evaluación del desempeño hospitalario en el SUS.
ABSTRACT
Introduction: Some benign breast diseases (BBD) can determine an increased risk of developing breast cancer. Environmental factors related to lifestyle and family history of breast cancer may be associated with BBD development. However, the effect of family history of breast cancer on the risk of benign breast diseases is still unclear. Objective: To evaluate the association between family history of breast cancer and benign breast diseases. Methods: This is an integrative review that selected observational studies in different databases to analyze the association between BBD and family history of breast cancer, considering the different classification criteria for both benign diseases and family history. All studies were published between 1977 and 2016. A total of 13 studies were selected, among which ten are case-control and case-cohort studies; and three are cohort studies. Most studies received high or moderate quality classification according to the Newcastle-Ottawa assessment scale. Results: Family history of breast cancer was associated with the development of proliferative lesions and the presence of atypia, and it was more closely related to the development of benign diseases in young women, with a tendency to decrease with advancing age. Conclusion: Studies suggest there may be an association between family history of breast cancer and benign breast diseases; nevertheless, no statistically significant results were found in many case-control studies, and more robust prospective research is necessary to further clarify this association.